UT Southwestern in Dallas will lead three liver cancer projects on prevention, recurrence, and immunotherapy. It joins Mayo Clinic and MD Anderson as a national NCI SPORE site, a program that moves discoveries into clinical trials.
“We’re quite honored to be chosen as a liver cancer SPORE. Our selection speaks to the quality of science and the potential for discovery and advances in clinical research and care at UT Southwestern,” said Amit Singal, professor of internal medicine and in the Peter O’Donnell Jr. School of Public Health, medical director of the Liver Tumor Program, and chief of hepatology at UTSW.
Beyond the three studies, UTSW said the SPORE will fund a Developmental Research Program for seed grants to launch high-risk, high-reward projects, and a Career Enhancement Program to support early-career scientists and clinicians in translational liver cancer research. For the full story, check out Dallas Innovates.
